Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Emmanuel Papadakis
DB
Emmanuel Papadakis
Deutsche Bank
Wall Street Analyst
★★☆☆☆
#2170
on 13Foresight · ranked by our own returns
33%
Success Rate
-11.6%
Average Return
4 of 12 calls profitable · -26.3% vs benchmark
📈 Across the calls we could measure, roughly 33% of Emmanuel Papadakis's ratings turned a profit when each position was held for 1 year — averaging -11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

81 Buy 68 Hold 24 Sell
Emmanuel's Stock Coverage 34 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:0QIU
Novo Nordisk
 Jun 19, 2026 HOLD Hold
+45.6% avg upside
28 analysts
$290.00
3.66% Upside
 ·
FR:SAN
Sanofi
 Jun 15, 2026 BUY Strong Buy
+33.0% avg upside
30 analysts
$95.00
27.06% Upside
 ·
CH:NOVN
Novartis AG
 Jun 09, 2026 BUY Buy
-10.2% avg upside
30 analysts
$135.00
13.52% Upside
 ·
GB:AZN
AstraZeneca
 Jun 09, 2026 SELL Strong Buy
+11.9% avg upside
26 analysts
$11500.00
13.31% Downside
 ·
GB:GSK
GlaxoSmithKline
 Jun 08, 2026 HOLD Hold
-3.3% avg upside
25 analysts
$1900.00
1.51% Downside
 ·
ZLDPF
Zealand Pharma
 Jun 04, 2026 HOLD Buy
+93.0% avg upside
11 analysts
$46.61
4.23% Upside
 ·
CH:ROP
Roche Holding AG
 May 27, 2026 HOLD Buy
+3.2% avg upside
23 analysts
$340.00
6.70% Upside
 ·
GB:0QW0
arGEN X
 May 15, 2026 BUY Strong Buy
-23.2% avg upside
24 analysts
$750.00
3.28% Downside
 ·
GB:0MGB
Genmab A/S
 May 11, 2026 BUY Buy
+32.3% avg upside
22 analysts
$2250.00
36.13% Upside
 ·
BNTX
BioNTech SE
 Mar 17, 2026 BUY Strong Buy
+50.5% avg upside
26 analysts
$140.00
54.06% Upside
 -4.2%
CH:SDZ
Sandoz Group Ltd
 Feb 26, 2026 HOLD Buy
-5.2% avg upside
10 analysts
$70.00
4.98% Upside
 ·
NVO
Novo Nordisk
 Feb 23, 2026 HOLD Buy
+168.1% avg upside
26 analysts
 — +13.8%
GB:0NZT
UCB SA
 Dec 08, 2025 BUY Buy
-13.5% avg upside
19 analysts
$295.00
17.85% Upside
 ·
ARGX
Argenx Se
 Sep 11, 2025 HOLD Strong Buy
-15.8% avg upside
46 analysts
 — +15.6%
ES:GRF
Grifols
 Aug 05, 2025 HOLD Buy
+62.8% avg upside
12 analysts
$12.00
33.13% Upside
 ·
ES:ALM
Almirall
 Jul 28, 2025 BUY Buy
+18.6% avg upside
5 analysts
$14.00
24.99% Upside
 ·
SE:SOBI
Swedish Orphan Biovitrum AB
 Jul 08, 2025 HOLD Strong Buy
-14.7% avg upside
6 analysts
$285.00
35.16% Downside
 ·
NL:LKFT
Galapagos
 Apr 28, 2025 HOLD Sell
+112.3% avg upside
16 analysts
$22.00
10.57% Downside
 ·
SNY
Sanofi
 Jan 30, 2025 HOLD Strong Buy
+74.9% avg upside
20 analysts
 — -9.3%
CH:IDIA
Idorsia Ltd
 Nov 29, 2024 HOLD Hold
-27.4% avg upside
8 analysts
$1.00
82.25% Downside
 ·
MRNA
Moderna
 Aug 06, 2024 HOLD Hold
+6.4% avg upside
38 analysts
$80.00
24.98% Upside
 -67.5%
LLY
Eli Lilly & Co
 Jul 17, 2024 HOLD Strong Buy
-10.5% avg upside
47 analysts
 — -15.3%
ALVO
Alvotech
 Jul 02, 2024 HOLD Buy
+104.1% avg upside
6 analysts
$14.00
257.16% Upside
 -27.0%
GRFS
Grifols SA
 Jun 18, 2024 HOLD Buy
+242.8% avg upside
12 analysts
 — +23.9%
FR:IPN
Ipsen
 Aug 07, 2023 HOLD Buy
-21.4% avg upside
17 analysts
$124.00
20.14% Downside
 ·
RHHBY
Roche Holding
 Jan 18, 2023 SELL Buy
+0.0% avg upside
14 analysts
 — +7.5%
GMAB
Genmab
 Nov 11, 2022 HOLD Buy
+38.2% avg upside
26 analysts
 — -24.8%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
 Aug 09, 2022 HOLD Hold
-9.8% avg upside
6 analysts
$44.00
12.94% Downside
 ·
LKFT
Lakefront Biotherapeutics
 Aug 06, 2021 HOLD Hold
+272.9% avg upside
24 analysts
$57.30
102.41% Upside
 ·
GSK
GlaxoSmithKline
 Apr 16, 2021 SELL Hold
-14.1% avg upside
19 analysts
 — -29.4%
HK:0013
HUTCHMED (China)
Jul 15, 2020 HOLD Buy
+619.8% avg upside
6 analysts
 — ·
DE:BAYN
Bayer
 Jul 14, 2020 BUY Strong Buy
+34.9% avg upside
28 analysts
$80.00
115.93% Upside
 ·
DE:MRK
Merck KGaA
 Jan 15, 2019 SELL Buy
+2.1% avg upside
32 analysts
$78.00
41.25% Downside
 ·
NVS
Novartis
 Dec 07, 2018 SELL Hold
-7.8% avg upside
24 analysts
 — -21.8%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Emmanuel Papadakis — Frequently Asked Questions
How accurate are Emmanuel Papadakis's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Emmanuel's ratings were profitable over a one-year hold, with an average return of -11.6% per rating, or -26.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Emmanuel ranked on 13Foresight?
Emmanuel Papadakis is currently ranked #2170 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Emmanuel cover?
Emmanuel most recently has ratings on GB:0QIU, FR:SAN, CH:NOVN, GB:AZN, GB:GSK, ZLDPF, CH:ROP, GB:0QW0, GB:0MGB, BNTX, CH:SDZ, NVO and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.